

Daclatasvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)

Indications

Chronic hepatitis C

Daclatasvir + sofosbuvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications

Chronic hepatitis C

Dasabuvir**Section**

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 250 mg tablet

Indications

Chronic hepatitis C

Elbasvir + grazoprevir**Section**

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 100 mg

Indications

Chronic hepatitis C

Entecavir**Section**

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg

Indications

Chronic hepatitis B

Glecaprevir + pibrentasvir**Section**

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications

Chronic hepatitis C

Ledipasvir + sofosbuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 90 mg + 400 mg tablet

Indications

Chronic hepatitis C

Ombitasvir + paritaprevir + ritonavir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

Chronic hepatitis C

Pegylated interferon alfa (2a)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

Chronic hepatitis C

Pegylated interferon alfa (2b)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

Chronic hepatitis C

Ravidasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg

Indications

Chronic hepatitis C

Ribavirin

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

Chronic hepatitis C

Simeprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 150 mg

Indications

Chronic hepatitis C

Sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg; 400 mg
- Oral > Solid > granules: 200 mg in sachet

Indications

Chronic hepatitis C

Sofosbuvir + velpatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

Chronic hepatitis C

Tenofovir alafenamide

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 25 mg

Indications

Chronic hepatitis B

Tenofovir disoproxil fumarate

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Chronic hepatitis B